分享好友 资讯首页 频道列表

Merck and Pfizer Initiate Two Phase III Studies of Investigational Immunotherapy Avelumab in Advance

2015-12-10 09:5120560

DARMSTADT, Germany & NEW YORK -- (BUSINESS WIRE) --

Merck and Pfizer today announced the initiation of two Phase III studies of avelumab*, an investigational, fully human anti-PD-L1 IgG1 monoclonal antibody, in treating advanced or metastatic gastric/gastro-esophageal junction (GEJ) cancers, which are aggressive cancers with poor survival rates. These pivotal trials are investigating avelumab in the first-line and third-line settings, with overall survival (OS) as the primary endpoint in both trials.

JAVELIN Gastric 100, a study comparing the switch from first-line chemotherapy to maintenance therapy with avelumab versus continuation of chemotherapy, is a multicenter, international, randomized, open-label Phase III trial designed to evaluate the potential superiority (based on OS) of maintenance therapy with avelumab in patients with unresectable, locally advanced or metastatic gastric/GEJ cancers whose disease has not progressed with first-line platinum-based chemotherapy. This is currently the only Phase III trial in gastric cancer that is designed to evaluate superiority of an immunotherapy compared with conventional platinum-based chemotherapy as a first-line maintenance treatment. The study will enroll 629 patients across more than 220 sites in Asia Pacific, Europe, North America and South America.

“The prognosis is generally poor for the majority of patients with advanced gastric cancers,” said Dr. Luciano Rossetti, Head of Global Research & Development at Merck’s biopharma business. “By initiating these two Phase III trials in gastric and gastro-esophageal junction cancers, we are continuing the fight against cancer with an overarching goal of potentially improving survival for patients.”

The third-line study, JAVELIN Gastric 300, is a multicenter, international, randomized, open-label Phase III trial designed to evaluate the potential superiority (based on OS) of avelumab in patients with unresectable, recurrent or metastatic gastric/GEJ cancers, compared with investigator’s choice of chemotherapy from a pre-specified list of therapeutic options. The study will enroll approximately 330 patients, spanning approximately 170 sites in Asia, Australia, Europe, North America and South America.

“We are continuing to investigate avelumab in cancers with high unmet need and where there is a strong rationale for immunotherapeutic intervention,” said Dr. Mace Rothenberg, Senior Vice President of Clinical Development and Medical Affairs and Chief Medical Officer for Pfizer Oncology. “Advanced gastric cancer is a challenging diagnosis to face as a patient, and we are dedicating significant resources to evaluate avelumab as a potential new treatment option for patients in multiple settings of this disease.”

The clinical development program for avelumab now includes more than 1,500 patients who have been treated across more than 15 tumor types, including breast cancer, gastric/GEJ cancers, head and neck cancer, Merkel cell carcinoma, melanoma, mesothelioma, non-small cell lung cancer, ovarian cancer, renal cell carcinoma and urothelial (e.g. bladder) cancer. Clinical trials for both of the gastric/GEJ Phase III trials in North America will be conducted on behalf of Merck by EMD Serono, the company’s US and Canadian biopharma business.

*Avelumab is the proposed International Non-proprietary Name for the anti-PD-L1 monoclonal antibody (MSB0010718C). Avelumab is under clinical investigation and has not been proven to be safe and effective. There is no guarantee any product will be approved in the sought-after indication by any health authority worldwide.

 

References

1.

 

Waddell T et al. Ann Oncol 2013;24 Suppl 6:vi57–63.

2.

 

Wadhwa R et al. Nat Rev Clin Oncol 2013;10(11):643–55.

3.

 

American Cancer Society. Survival rates for stomach cancer, by stage. Available from: http://www.cancer.org/cancer/stomachcancer/detailedguide/stomach-cancer-survival-rates. Last accessed December 2015.

4.

 

National Cancer Institute Surveillance Epidemiology and End Results (SEER). SEER Stat Fact Sheets: Stomach Cancer. Available from: http://seer.cancer.gov/statfacts/html/stomach.html. Last accessed April 2015.

5.

 

International Agency for Research on Cancer (IARC)/EUCAN. Gastric cancer: Estimated incidence, mortality & prevalence for both sexes, 2012. Available from: http://eco.iarc.fr/EUCAN/Cancer.aspx?Cancer=8#block-table-a. Last accessed April 2015.

6.

 

Mayo Clinic. Stomach cancer treatments and drugs. Available from: http://www.mayoclinic.org/diseases-conditions/stomach-cancer/basics/treatment/con-20038197. Last accessed April 2015.

7.

 

Buas MF & Vaughan TL. Semin Radiat Oncol. 2013; 23(1): 3–9.

8.

 

Cunningham D et al. New Eng J Med 2006;355(1):11–22.

9.

 

Macdonald JS et al. N Eng J Med 2001;345(10):725–30.

10.

 

Cancer Research UK. What is advanced oesophageal junction cancer? http://www.cancerresearchuk.org/about-cancer/type/oesophageal-cancer/treatment/advanced/what-is-advanced-oesophageal-cancer. Last accessed September 2015.

   

 

About Gastric and Gastro-esophageal Junction (GEJ) Cancers

Gastric cancer is uncommon in the US and Western Europe.1,2 Each year, there are approximately 22,000 new cases of gastric cancer diagnosed in the US and 80,626 cases diagnosed in the EU.3 Gastric cancer is much more commonly diagnosed in East Asia, Eastern Europe, and parts of South America.4 For patients with advanced gastric cancer, the prognosis is poor. The 5-year survival rate in the US is <20 percent for Stage III gastric cancer and <5 percent for Stage IV gastric cancer.5 Current treatment options for gastric cancer may include surgery, radiotherapy, chemotherapy, chemoradiotherapy and targeted therapies.2,6

Reliable data on the global incidence of GEJ tumors are not available, due to the historically complicated classification system and the likelihood of misclassification.7 Current treatment options for GEJ cancer may include surgery, chemotherapy, radiation therapy and targeted therapy.8,9 Despite advances in the field of GEJ, there is no cure for patients with cancer that has spread.10 There is a clear unmet medical need for new treatment options.

About Avelumab

Avelumab (also known as MSB0010718C) is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody. By inhibiting PD-L1 interactions, avelumab is thought to enable the activation of T-cells and the adaptive immune system. By retaining a native Fc-region, avelumab is thought to potentially engage the innate immune system and induce antibody-dependent cell-mediated cytotoxicity (ADCC). In November 2014, Merck and Pfizer announced a strategic alliance to co-develop and co-commercialize avelumab.

About Merck-Pfizer Alliance

Immuno-oncology is a top priority for Merck and Pfizer. The global strategic alliance between Merck and Pfizer enables the companies to benefit from each other’s strengths and capabilities and further explore the therapeutic potential of avelumab, an investigational anti-PD-L1 antibody initially discovered and developed by Merck. The immuno-oncology alliance will jointly develop and commercialize avelumab and advance Pfizer’s PD-1 antibody. The companies will collaborate on up to 20 high-priority immuno-oncology clinical development programs, including combination trials, many of which are expected to commence in 2015.

Pfizer Inc.: Working together for a healthier world®

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines, as well as many of the world's best-known consumer healthcare products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more, please visit us at www.pfizer.com.

About Merck

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 40,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2014, Merck generated sales of € 11.3 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

Pfizer Disclosure Notice

The information contained in this release is as of December 9, 2015. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about avelumab (MSB0010718C), including a potential indication for avelumab for gastric/gastro-esophageal junction cancers, Pfizer’s and Merck’s immuno-oncology alliance involving anti-PD-L1 and anti-PD-1 therapies, and clinical development plans, including their potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical study commencement and completion dates as well as the possibility of unfavorable study results; risks associated with interim data; the risk that clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate, regulatory authorities may not share our views and may require additional data or may deny approval altogether; whether and when drug applications may be filed in any jurisdictions for any potential indications for avelumab, combination therapies or other product candidates; whether and when any such applications may be approved by regulatory authorities, which will depend on the assessment by such regulatory authorities of the benefit-risk profile suggested by the totality of the efficacy and safety information submitted; decisions by regulatory authorities regarding labeling and other matters that could affect the availability or commercial potential of avelumab, combination therapies or other product candidates; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014, and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the SEC and available at www.sec.gov and www.pfizer.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151209005943/en/

 

CONTACT:

Merck
Media:
Gangolf Schrimpf, +49 6151 72 9591
or
Investor Relations:
+49 6151 72 3321
or
Pfizer
Media:
Sally Beatty, +1 212 733 6566
or
Investor Relations:
Ryan Crowe, +1 212 733 8160

反对 0
举报 0
收藏 0
打赏 0
评论 0
Takeda的HyHubTM和HyHubTM Duo装置获FDA 510(k)批准,简化HYQVIA给药流程
HyHub和HyHub Duo减少了HYQVIA的准备步骤1 作为Takeda的广泛、差异化产品组合中首款为血浆衍生疗法定制的装置,体现了公司对于提供以患者为中心的支持生态系统的承诺 结合患者和护理人员的意见研发,助力改善家庭输注体验 日本大阪和马萨诸塞州坎布里奇--(美国商业资讯)--Takeda ( TSE:4502/NYSE:TAK )今日宣布,美国食品药品管理局(FDA)已向HyHubTM和HyHubTM Duo授予510(k)批准。这两款装置适用于17岁及以上患者,在家庭环境或临床场...

0评论2025-07-231884

KIOXIA推出业界首款245.76 TB NVMe SSD,专为生成式AI环境需求打造
KIOXIA LC9系列成为容量最高的PCIe 5.0企业级SSD;采用32层堆叠BiCS FLASH(TM) QLC 3D闪存 东京--(美国商业资讯)--Kioxia Corporation扩展了其高容量KIOXIA LC9系列企业级SSD产品线,推出业界首款[1] 245.76太字节(TB)[2] NVMe™ SSD,提供2.5英寸和EDSFF E3.L两种规格。这一新的容量和规格选项与此前发布的122.88 TB(2.5英寸)型号形成互补,专为满足生成式AI环境对性能和效率...

0评论2025-07-231759

Omdia:云平台驱动129亿美元规模的游戏市场生态系统
伦敦--(美国商业资讯)--Omdia的最新分析显示,云平台是一个规模达129亿美元的技术生态系统的核心,为游戏行业的大部分领域提供支撑。这一生态系统涵盖从游戏服务器、后端工具到分析和实时运营(LiveOps)的方方面面——这些都是支撑现代游戏市场的关键技术。云平台正日益成为新兴AI应用的重要推动力,而这些应用有望改变游戏技术格局。 《Omdia Market Radar:2025年游戏云平台》(Omdia Market Radar: Cloud Platform...

0评论2025-07-231838

500 Global聘请联合国可持续发展目标(SDG)设计师Alaa Murabit博士,推出公司可持续增长新业务
《时代》百大人物、盖茨基金会前成员、全球安全领袖Alaa Murabit博士将领导500 Global在新兴市场的可持续增长业务,推动公司在扩大混合金融及公私合作投资模式方面的承诺,以释放创新潜力并促进包容性经济发展。 旧金山--(美国商业资讯)--500 Global是全球最活跃的风险投资公司之一1。该公司今日宣布任命Alaa Murabit博士为可持续增长业务管理合伙人。她将负责监督公司的可持续增长业务,该业务旨在调动前沿市场和新兴市场中气候、健康及人类发展领域的资本与资源,从而增强经济韧...

0评论2025-07-231623

SS&C Technologies将收购Calastone
康涅狄格州温莎--(美国商业资讯)--SS&C Technologies Holdings, Inc. (Nasdaq: SSNC)今日宣布达成一项最终协议,将从跨国投资公司Carlyle手中收购Calastone。Calastone是全球最大的基金网络,也是财富与资产管理行业技术解决方案的领先提供商。收购价格约为7.66亿英镑(约合10.3亿美元),具体金额可能会有某些调整。 Calastone总部位于伦敦,运营着全球最大的基金网络,连接着57个市场中超过4500家全球领先的金...

0评论2025-07-231726

Cloudbreak Pharma Inc.宣布CBT-004治疗血管化睑裂斑患者的2期临床试验取得积极结果
新型无防腐剂CBT-004滴眼液配方在结膜充血及患者报告症状方面展现出具有统计学意义的改善,且安全性优异 加州尔湾--(美国商业资讯)--Cloudbreak Pharma Inc.是一家处于临床阶段的眼科公司,致力于开发针对眼表疾病的创新疗法。该公司今日宣布,其评估CBT-004眼用溶液治疗血管化睑裂斑及相关结膜充血患者的2期临床试验取得积极顶线结果。 2期临床试验关键结果 达到主要终点:独立阅片中心通过数字成像评估显示,在第28天,两种受试浓度的CBT-004与溶媒对照组相比,结膜...

0评论2025-07-231071

Access Advance 宣布 HEVC Advance 和 VVC Advance专利池直至 2030 年的专利费定价
波士顿--(美国商业资讯)--Access Advance LLC(“Advance”)今天宣布了HEVC Advance 和 VVC Advance专利池的许可方做出的几项重大决定。两个专利池均选择对在 2025 年 12 月 31 日之前签署的被许可方维持其当前的专利费的费率和上限,并对同期签署 Advance 多编解码器桥接协议(“MCBA”)的被许可方延长激励措施,使 Advance 的多编解码器桥接协议 (“MCBA&rd...

0评论2025-07-231263

Mapxus 攜手 Ricoh 推動室內數位地圖與 360 度全景應用創新
香港--(美國商業資訊)--Mapxus Technology(創辦人暨執行長:陳尊裕博士,以下簡稱「Mapxus」)宣布與 Ricoh Company, Ltd.(理光株式會社)(總裁暨執行長:大山晃,以下簡稱「Ricoh」)建立技術合作夥伴關係,攜手推動室內數位地圖和 360 度全景應用的創新發展。透過此次合作,用戶可更高效地運用 Mapxus 服務打造室內定位導航系統及虛擬導覽,有效簡化工作流程並提升營運效率。 Mapxus 將與 Ricoh 的「RICOH360」平台整合,並利用...

0评论2025-07-231868

智原推出DDR/LPDDR通用物理层IP解决方案 适用于联电22ULP与14FFC工艺
台湾 新竹--(美国商业资讯)--ASIC设计服务暨IP研发领导厂商智原科技(Faraday Technology Corporation)今日宣布推出可支持第三至第五代DDR/LPDDR的通用物理层IP,适用于联电(UMC)22ULP与14FFC FinFET工艺。智原持续致力于提供优化的自有IP解决方案,协助ASIC客户提升开发效率与产品成本竞争力。 智原的DDR/LPDDR物理层IP解决方案,已广泛应用在多项SoC设计案中,已通过硅验证及单芯片系统整合验证,其高度稳定性与兼容性完全...

0评论2025-07-231019

迪拜推出全球首个人机协作研究出版图标分类系统
该分类体系为 AI 辅助知识创作时代设立透明度新标准 阿拉伯联合酋长国迪拜--(美国商业资讯)--迪拜推出全球首个基于图标的分类系统,用于展示在研究、出版物和面向公众的内容制作过程中,人机协作的程度。 本新闻稿包含多媒体。此处查看新闻稿全文: https://www.businesswire.com/news/home/20250717268886/zh-CN/ 由Dubai Future Foundation (DFF) 开发的人机协作图标(HMC Icons),为透明度提供了新的全...

0评论2025-07-231820